DEF 14A: Ocular Therapeutix Seeks Stockholder Approval for Key Proposals at 2024 Annual Meeting

Ocular Therapeutix is holding its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on several proposals, including the election of directors, executive compensation, and amendments to the stock incentive plan and corporate charter.

Summary

• Ocular Therapeutix, Inc. is holding its 2024 Annual Meeting of Stockholders on June 12, 2024, in a virtual format.
• Stockholders will vote on the election of two Class I directors, an advisory vote on executive compensation, an amendment to the 2021 Stock Incentive Plan to increase the number of shares by 7,000,000, and an amendment to the Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares.
• The board of directors recommends voting FOR all proposals.
• The record date for determining stockholders eligible to vote is April 19, 2024.
• The company is using notice and access rules to provide proxy materials online, reducing paper and mailing costs.
• Pravin U. Dugel, M.D., is the Executive Chairman, President, and Chief Executive Officer of Ocular Therapeutix.
• Stockholders can vote online, by telephone, or by mail prior to the meeting, or online during the meeting.
• A majority of outstanding shares is required for a quorum.
• Approval of the amendment to the Restated Certificate of Incorporation requires a majority of outstanding common stock to vote FOR the proposal.
• The board has determined that all directors, except for Dr. Dugel, are independent.
• The company has a compensation recovery (clawback) policy in place.
• The company's insider trading policy prohibits short sales and derivative transactions of company stock by officers, directors, and employees.
• The company's compensation committee approved annual bonus targets for 2024 of 65% for the CEO and 45% for other named executive officers.
• The company maintains a 401(k) plan with matching contributions up to $2,500 per employee.
• The company's audit committee has recommended that the audited financial statements be included in the Annual Report on Form 10-K for the year ended December 31, 2023.
• PricewaterhouseCoopers LLP has been appointed as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The company is seeking stockholder approval to increase the number of shares issuable under the 2021 Stock Incentive Plan by 7,000,000 shares.
• The company's overhang as of March 31, 2024, was 17%, and would be 22% if the proposed share pool increase is approved.
• The company's three-year average burn rate is 5.6%.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the proposals for the annual meeting. The tone is professional and forward-looking, with an emphasis on attracting and retaining talent and providing flexibility for future business needs. The sentiment is neutral to slightly positive.

Positives

• The company is using notice and access rules to reduce paper and mailing costs.
• The board has determined that all directors, except for Dr. Dugel, are independent.
• The company has a compensation recovery (clawback) policy in place.
• The company's insider trading policy prohibits short sales and derivative transactions of company stock by officers, directors, and employees.
• The company maintains a 401(k) plan with matching contributions up to $2,500 per employee.
• The audit committee has recommended that the audited financial statements be included in the Annual Report on Form 10-K.
• PricewaterhouseCoopers LLP has been appointed as the independent registered public accounting firm.
• The company is seeking to increase the number of shares issuable under the 2021 Stock Incentive Plan to attract, retain, and motivate key employees.

Negatives

• The company's overhang as of March 31, 2024, was 17%, and would be 22% if the proposed share pool increase is approved, which could dilute existing stockholders.
• The company's three-year average burn rate is 5.6%, indicating a significant use of equity compensation.

Risks

• Failure to approve the amendment to the 2021 Stock Incentive Plan could hinder the company's ability to attract, retain, and motivate key employees.
• The issuance of additional shares of common stock may have a dilutive effect on earnings per share and on stockholders' equity and voting rights.
• Future sales of substantial amounts of the company's common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of the common stock or limit the company's ability to raise additional capital.
• The company's reliance on equity financings to fund operations could lead to further dilution of existing stockholders.

Future Outlook

The company anticipates that it may issue additional shares of common stock in the future in connection with financing transactions, collaborations, equity incentive plans, strategic investments, and other corporate purposes.

Management Comments

• The board of directors believes that our success depends, in large part, on our ability to maintain a competitive position by attracting, retaining and motivating key employees with experience and ability.
• The ability to grant equity awards is therefore critical to our ability to attract, retain and motivate top talent and is a key component of our compensation program.
• The board of directors believes that it is in the best interests of our company and our stockholders to increase the number of authorized shares of common stock to give us greater flexibility in considering and planning for potential business needs.

Industry Context

The document highlights the competitive landscape for talent in the biotechnology/pharmaceutical industry, where equity incentives are a central component of compensation packages.

Comparison to Industry Standards

• The document benchmarks executive compensation against a peer group of publicly traded companies in the biotechnology/pharmaceutical industry.
• The company retained Aon's Human Capital Solutions practice to provide comparative data on executive compensation practices.
• The company's compensation committee periodically reviews information regarding the independence and potential conflicts of interest of Aon, taking into account the factors set forth in the Nasdaq listing standards.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a consulting agreement with Heier Consulting, LLC, an entity affiliated with Dr. Heier, a former member of the board of directors, to advise on development efforts relating to retinal diseases.
• In October 2022, the company entered into a consulting agreement with Heier Consulting, LLC, an entity affiliated with Dr. Heier, a former member of our board of directors, to advise on our development efforts relating to retinal diseases.
• In August 2023, the company amended the Heier Consulting Agreement to extend the term of the Heier Consulting Agreement until June 30, 2024 and granted Dr. Heier an additional option to purchase 17,350 shares of our common stock at an exercise price per share of $4.30 and which vests in equal monthly installments over a term of one year beginning on July 1, 2023.
• On February 21, 2024, the Company entered into an employment agreement with Dr. Heier, or the Heier Employment Agreement, under which Dr. Heier agreed to serve as Chief Scientific Officer of the Company on a part-time basis, working 50% of a full-time schedule.
• In March 2019, the company issued a convertible note in the aggregate principal amount of $37.5 million to an entity affiliated with Summer Road LLC.
• Since 2014, the company has engaged Wilmer Cutler Pickering Hale and Dorr LLP, or WilmerHale, to provide legal services to us, including with respect to general corporate, finance, securities law, regulatory and licensing matters.

Stakeholder Impact

• Approval of the proposals is intended to benefit stockholders by enhancing the company's ability to attract and retain talent and pursue strategic opportunities.
• Employees may benefit from increased equity ownership opportunities and performance-based incentives.
• The company's financial position may be strengthened by the increased flexibility to issue shares for financing transactions and collaborations.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on June 12, 2024.
• The company intends to file the amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware if the proposal is approved.
• The company intends to register the additional shares reserved for issuance under the Amended Plan by filing a Registration Statement on Form S-8 as soon as reasonably practicable following stockholder approval.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, executive compensation, stock incentive plan, authorized shares, PricewaterhouseCoopers, ocular therapeutix, governance